REVBW · Revelation Biosciences, Inc. · Executive Compensation
$0.01
At close · Oct 26
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that our unaudited financial statements for June 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$2.16M
Shares
569,059
Volume · Oct 26
866
Avg daily vol (3M)
24.11K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Chester S. Zygmont, III | Chief Financial Officer | Appointed | 2026-06-24 |
| James Rolke | Chief Executive Officer | Appointed | 2026-06-24 |
| Jennifer Carver | Class A director | Appointed | 2026-06-24 |
| George Tidmarsh, M.D., Ph.D. | Class C Director | Resigned | 2025-05-28 |
| Lakhmir Chawla M.D. | Class C Director | Appointed | 2023-10-02 |
| Curt LaBelle, M.D. | Board of Directors | Resigned | 2023-10-02 |
Leadership
- James Rolke CEO, Board Member
- Chester S. Zygmont CFO
- Chester S. Zygmont, III CFO
- Anthony Hayes Board Member
- George F. Tidmarsh Board Member
- Jennifer Carver Board Member
- Jess Roper Board Member
- Lakhmir Chawla Board Member
- Lakhmir Chawla M.D. Board Member
- William H. Carson Board Member